Research in the Padmini Ranasinghe Lab focuses on internal and preventive medicine, with an emphasis on health and wellness and international health.

Research in the Kawsar Rasmy Talaat Lab focuses on international health and parasitology, with an emphasis on vaccines, avian influenza and pandemic influenza. Our team conducts clinical trials of vaccines for a range of diverse pathogens, including flu strains that have the potential to reach pandemic status. Our studies seek to evaluate the safety and immunogenicity of vaccine candidates. We also have a longstanding interest in tropical medicine.

The Anna Durbin Lab evaluates experimental vaccines through human clinical trials. We have conducted both pediatric and adult clinical trials on vaccines for HIV, hepatitis C, HPV, influenza, malaria, dengue virus, rotavirus and other viruses. We also have a longstanding interest in better understanding the immunologic factors of dengue infection and disease. We’re working to identify the viral, host and immunologic factors that cause severe dengue illness.

Research in the David Sack Lab focuses on enteric infections. Our team has worked to develop laboratory detection methods to better understand the epidemiology of these agents. We also work to create appropriate clinical management strategies, such as antibiotics and rehydration methods, for enteric infections. Our work has included participating in the development of vaccines for a range of bacterial infections, including rotavirus, cholera and enterotoxigenic E. coli.

Research in the William Checkley Lab explores the field of lung health, with an emphasis on the epidemiology of obstructive lung diseases as well as acute lung injury and mechanical ventilation. We also explore the interactions between nutrition and infection, and the impact of environmental exposures to health.

Our IndoUS team, based both in Baltimore and in India, specializes in international clinical research (cohort studies and clinical trials), public health implementation science and education in infectious diseases, HIV/AIDS, tuberculosis (TB), vaccine preventable illnesses, antimicrobial resistant infections, and more recently COVID. Since 2003, our work has been focused primarily on India, where we are engaged in several Indo-JHU and international research collaborations. We partner with several leading medical and research institutions in India (e.g. BJGMC, DY Patil, Hinduja Hospital, KEM, Bharati Vidyapeeth, NIRT, JIPMER, CMC, Medanta, IISER, YRG, IIT), as well as others in sub-Saharan Africa, US and Brazil. We are actively involved in the following consortia: 1) Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. 2) RePORT International TB Research Consortium, a multilateral global consortia for TB research, 3) US NIH funded multi-country HIV and TB trials consortia of the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT) Network, 4) NIH and AmFAR funded IeDea HIV/TB Working Group and the Treat Asia-IeDEA HIV and TB epidemiology databases, and 5) CDC SHEPHERD AMR studies. Our group has been awarded research grants from the US NIH, US CDC, UNITAID, Indian government, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond.

The key research interests in the Robert Bollinger Lab include identifying biological and behavioral risk factors for HIV transmission as well as characterizing the clinical progression and treatment of HIV and related infectious diseases. We also have a long-standing interest in optimizing health care capacity and delivery in settings with limited resources. Our work includes implementing science research projects to explore the effectiveness of initiatives such as task-shifting, clinical education, distance learning and mobile health programs as a way to improve health care in these locations.

Research in the Robert Gilman Lab focuses on disease control. Our work led to the development of microscopic-observation drug-susceptibility (MODS), a rapid tuberculosis diagnostic technique. We continue to conduct infectious disease research based at Peru’s Universidad Peruana Cayetano Heredia.